122 Participants NeededMy employer runs this trial

Ivermectin for Pancreatic Cancer

Recruiting at 6 trial locations
AG
EO
Overseen ByEileen O'Reilly, MD
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: Memorial Sloan Kettering Cancer Center
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

The researchers are doing this study to find out whether the combination of ivermectin and standard of care prophylaxis (SOCP; drugs given to prevent the development of a disease or condition) is an effective treatment approach for people with skin side effects caused by daraxonrasib treatment (daraxonrasib-induced skin toxicity). The researchers will compare the combination of ivermectin and SOCP with SOCP alone to see which treatment approach is more effective. The researchers will also look at how the study treatments impact participants' quality of life. The researchers will measure quality of life by having participants complete questionnaires.

Who Is on the Research Team?

AG

Allison Gordon, MD

Principal Investigator

Memorial Sloan Kettering Cancer Center

Are You a Good Fit for This Trial?

This trial is for people with pancreatic cancer who are experiencing skin side effects from the drug daraxonrasib. Participants must be able to use creams and medications on their skin as part of the study.

Inclusion Criteria

Not pregnant and not nursing
I have advanced pancreatic ductal adenocarcinoma and plan to take daraxonrasib alone.
I do not have an active infection needing IV antibiotics.
See 4 more

Exclusion Criteria

Documented allergy to oral ivermectin and/or minocycline
Any condition which, in the investigator's opinion, makes the patient unsuitable for trial participation
Pregnancy or planned pregnancy during the study period
See 3 more

What Are the Treatments Tested in This Trial?

Interventions

  • Ivermectin

Trial Overview

The study compares standard treatments for skin problems (like steroid creams, antibiotics, and photoprotection) with or without adding ivermectin to see which works better at preventing or treating daraxonrasib-related skin issues.

How Is the Trial Designed?

2

Treatment groups

Experimental Treatment

Active Control

Group I: Ivermectin 200 mcg/kg orally weekly plus SOCPExperimental Treatment7 Interventions
Group II: SOCP aloneActive Control6 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

Memorial Sloan Kettering Cancer Center

Lead Sponsor

Trials
1,998
Recruited
602,000+